The receptor for the type 1 insulin-like growth factor (IGF-I) regulates multiple cellular functions impacting on the metastatic phenotype of tumor cells, including cellular proliferation, anchorage-independent growth, survival, migration, synthesis of the 72-kDa type IV collagenase and invasion. We have used site-directed mutagenesis to generate domain-specific mutants of the receptor ␤ subunit to analyze the role of specific tyrosines in the regulation of the invasive/metastatic phenotype. Poorly invasive M-27 carcinoma cells expressing low receptor numbers were transfected with a plasmid vector expressing IGF-I receptor cDNA in which single or multiple tyrosine codons in the kinase domain, namely Tyr-1131, Tyr-1135, and Tyr-1136 or the C-terminal tyrosines 1250 and 1251 were substituted with phenylalanine. Changes in the invasive and metastatic properties were analyzed relative to M-27 cells expressing the wild type receptor. We found that cells expressing the Y1131F,Y1135F,Y1136F or Y1135F receptor mutants lost all IGF-IR-dependent functions and their phenotypes were indistinguishable from, or suppressed relative to, the parent line. The Y1250F,Y1251F substitution abolished anchorage-independent growth, cell spreading, and the anti-apoptotic effect of IGF-I whereas all other IGF-IR-dependent phenotypes were either unperturbed (i.e. mitogenicity) or only partially reduced (migration and invasion). The results identify three types of receptor-dependent functions in this model: those dependent only on an intact kinase domain (DNA synthesis), those dependent equally on kinase domain and Tyr-1250/1251 signaling (e.g. apoptosis, soft agar cloning) and those dependent on kinase domain and enhanced through Tyr-1250/1251 signaling (migration, invasion). They suggest that signals derived from both regions of the receptor cooperate to enhance tumor metastasis.
Cancer metastasis is a complex multistep process involving sequential interactions between the disseminating tumor cells and a continuously changing host microenvironment. These interactions include cell-cell and cell-extracellular matrix communication mediated through specific adhesion receptors, such as integrins, which regulate tumor cell attachment, spreading, and migration (1, 2) , the dissolution of tissue barriers through the degradative activity of enzymes such as metallo-and serine-proteinases (3, 4) and growth modulation by paracrine, host-derived peptide growth factors (5, 6) .
The human receptor for the type 1 insulin-like growth factor (IGF-IR) 1 is a heterotetramer consisting of two 130-to 135-kDa ␣ and two 90-to 95-kDa ␤ subunits with several ␣-␣ and ␣-␤ disulfide bridges (7) . It is synthesized as a single polypeptide chain, which is then glycosylated and proteolytically cleaved into the ␣ and ␤ subunits (8) . The ligand-binding domain is located on the extracellular ␣ subunit. Approximately one-third of the ␤ subunit is extracellular and is connected to the intracellular portion by a single transmembrane domain. The intracellular region of the ␤ subunit has a binding site for phosphorylation substrates at tyrosine residue 950, an ATP-binding site at lysine 1003, a tyrosine kinase domain with three critical tyrosines at positions 1131, 1135, and 1136 and several tyrosines in the C-terminal domain at positions 1250, 1251, and 1316 known to regulate some receptor functions (9 -11) .
Recent studies have shown that the receptor plays a crucial role in the induction and maintenance of the malignant phenotype (12, 13) . Overexpression and/or constitutive activation of the IGF-IR lead to acquisition of a transformed phenotype (measured as growth in semi-solid agar) and tumorigenic potential (growth in immunodeficient mice) in various cell types (14) . The IGFs are potent mitogens for a range of tumor cell types in vitro, and increased expression of IGF-I, IGF-II, and IGF-IR or a combination thereof have been documented in many human malignancies, including carcinomas of the lung, breast, thyroid, gastrointestinal tract and prostate, glioblastomas, neuroblastomas, rhabdomyosarcomas, and leukemias (reviewed in Ref. 15) . Several oncogenes were shown to affect IGF-I and IGF-IR expression. Oncogene c-myb induces the expression of both IGF-I and IGF-IR whereas tumor suppressors WT1 and p53 reduce IGF-IR levels (13) . Suppression of IGF-IR by antisense oligodeoxynucleotides (16, 17) , stable transfection with plasmid vectors expressing IGF-IR antisense cDNA (18, 19) , IGF-I peptide analogues (20) , triple-helix forming oligodeoxynucleotides (21) , and single chain antibodies (22) have all been shown to suppress tumor cell growth in vivo (reviewed in Ref. 23 ). In a series of studies, using two subclones of the Lewis lung carcinoma, we have recently documented a correlation between IGF-IR levels and the metastatic potential of the cells, particularly to the liver and have shown that a reduction in IGF-IR levels by antisense mRNA leads to abrogation of the metastatic phenotype whereas receptor overexpression results in the acquisition of a highly invasive/metastatic phenotype (19, 24) .
Mutational analyses of the receptor, based mainly on the study of fibroblast cell lines have recently shown that the mitogenic, transforming, and cell survival functions of the IGF-IR can be segregated to different domains of the receptor ␤ subunit. The data suggested that the receptor can probably utilize several distinct signaling pathways that may either involve, or be independent of, the known receptor substrates IRS-1 and Shc (9, (25) (26) (27) (28) (29) 30) .
Because overexpression of IGF-IR in M-27 cells altered multiple cellular functions, all of which can impact on the metastatic phenotype (24), we sought here to utilize this model to gain insight into the molecular mechanisms that regulate metastasis-related functions of the receptor. M-27 cells were therefore transfected with plasmid vectors expressing receptor cDNA in which tyrosines in the kinase and C-terminal domains of the receptor ␤ subunit were substituted with phenylalanines. The effect of these substitutions on different cellular functions that impact on the metastatic phenotype were then analyzed.
EXPERIMENTAL PROCEDURES
Cell Lines-The origin, properties, metastatic phenotype, and methods of transplantation for M-27, a clonal subline of the Lewis lung carcinoma, were described in detail previously (24, 31) . In vivo, M-27 cells form subcutaneous tumors, are moderately metastatic to lung following tail vein injection but do not spontaneously metastasize to extrapulmonary sites (31, 32) . This tumor line is maintained by subcutaneous implantation of isolated lung metastases derived from tumorbearing mice into new recipient animals. Monolayer cultures are prepared from dispersed tumors and maintained in vitro for up to 4 weeks in RPMI medium supplemented with 10% FCS. A second subline of the Lewis lung carcinoma, line H-59, was used for some experiments. Its origin and properties have been described in detail in our previous communications (6, 31, 32, 34) .
Generating and Cloning IGF-IR Mutants-A full-length human IGF-IR cDNA was amplified by PCR from the pCVN plasmid (24) , cloned into the pMOSBlue transfer vector (Amersham Pharmacia Biotech, Oakville, Ontario, Canada) and then subcloned into the pCI expression vector (Promega, Madison, WI) using the XbaI-EcoRI cloning sites. A neomycin-resistance gene under the control of an SV-40 promoter was cloned into the HpaI site of the same vector. To generate IGF-IR mutants with Y-F substitutions, a two-step recombinant PCR method was used (33) . Full-length IGF-IR cDNA in pCVN was used as template. For each mutation, two common external primers spanning nucleotides 2564 -2591 (P1-sense) and nucleotides 4139 -4160 (P4-antisense) were used together with two unique internal primers (P2-sense and P3-antisense, respectively) containing base substitutions in the target tyrosine codons. The primary PCR products of the P1/P2 and P3/P4 reactions with 24-to 27-bp overlaps were mixed, and a 1596-bp fragment was synthesized by 3Ј-extension of the heteroduplex using the two external primers P1 and P4 described above. The P2 and P3 internal primers (5Ј and 3Ј, respectively) were as follows: for Y1131F: 5Ј-CGCGAGATATCTTCGAGACAG-3Ј and 5Ј-CTGTCTCGAAGATAT-CTCGCG-3Ј(antisense) for Y1135F; 5Ј-GATATCTATGAGACAGACTT-CTACCGG-3Ј(sense) and 5Ј-CCGGTAGAAGTCTGTCTCATAGATATC (antisense) for Y1131F,Y1135F,Y1136F; 5Ј-CGAGATATCTTCGAGAC-AGACTTCTTCCGG-3Ј (sense) and 5Ј-CCGGAAGAAGTCTGTCTCGA-AGATATCTCG-3Ј and for Y1250F,Y1251F; 5Ј-GAGGTCTCCTTCTTC-TTCAGCGAG-3Ј and 5Ј-CTCGCTGAAGAAGAAGGAGACCTC-3Ј. Mutated codons are indicated by underlining. Amplification was carried out in a PTC-100 Programmable Thermal Controller (Atomic Energy of Canada Ltd., Montreal, Quebec, Canada) using established procedures as we previously described (19, 34) , and the amplified DNA fragments were cloned into the pMOSBlue (Amersham Pharmacia Biotech, Baie d'Urfe, Quebec, Canada) multiple cloning region and then subcloned into the pCI-Neo-IGF-IR plasmid. All the mutations were confirmed by digestion with multiple restriction enzymes and manual dideoxy sequencing.
Transfection-The IGF-IR constructs were transfected into M-27 cells using Lipofectin, as we previously described (24) . Cells were cultured in RPMI-FCS supplemented from day 2 onward with 200 g/ml G418 (Life Technologies, Inc., Burlington, Ontario, Canada). Neomycinresistant cells were maintained in G418-containing medium throughout the experimental period. M-27 cells transfected with the pCI-neo vector as control were indistinguishable with respect to all phenotypes examined from non-transfected M-27 cells.
Ligand Binding Assay-IGF-I binding sites on the tumor cells were quantitated using the method of Phillips et al. (35) . Briefly, tumor cells in 24-well plates were washed with serum-free (SF)-RPMI medium, incubated for 1 h at 37°C with 8 -1500 pM of 125 I-labeled IGF-I (2000 Ci/mmol from Amersham) in binding medium (SF-RPMI containing 1 mg/ml bovine serum albumin and 1 g/ml leupeptin) with or without graded concentrations of unlabeled rH-IGF-I, rinsed with ice-cold binding medium, solubilized in 0.01 N NaOH containing 0.1% Triton X-100 and 0.1% SDS, and the radioactivity was measured in an LKB gamma counter. The number of cells/well at the time of the assay was determined from triplicate control wells, which were manipulated in the same manner and the number of IGF-I binding sites calculated using the Ligand program (36) .
Cell Spreading on Fibronectin-Twenty-four-well plates were precoated with 10 g/ml fibronectin/well. To each well 2 ϫ 10 4 cells in RPMI-FCS were added, and the cells were incubated first at room temperature for 30 min and then at 37°C for up to 5 h. Unattached cells were removed by repeated washing, and the remaining cells were fixed and enumerated using phase contrast microscopy. Cells in each of 20 random fields per well were scored as being either spread (phase dark cell extending cellular processes) or non-spread (phase bright and rounded) (37) .
Thymidine Incorporation and Soft Agar Cloning-These assays were performed essentially as we previously described (19) . Thymidine incorporation was measured after the cells were incubated with increasing concentrations of rHIGF-I (Intergen, Purchase, NY) at 37°C for 72 h, and agar colonies were enumerated following a 12-day incubation in RPMI containing 10% FCS. Colonies that exceeded 250 m in diameter were scored using an inverted microscope (Diaphot-TMD Inverted, Nikon Canada).
Apoptosis-Apoptosis was analyzed using the annexin V immunostaining assay. Tumor cells in monolayer cultures were grown to 80% confluency, the serum-containing medium was removed, and the cells were washed repeatedly to remove traces of serum and then incubated for 48 h in SF-RPMI containing or not 10 ng/ml IGF-I. The proportion of cells undergoing apoptosis was measured by flow cytometry using the Annexin-V-Fluos staining kit (Roche Molecular Biochemicals) as instructed by the manufacturer.
Analysis of Matrix Metalloproteinase-2 Expression-MMP-2 expression was analyzed by RT-PCR, Western blotting, and gelatin zymography. All the analyses were performed essentially as we have previously described (34) . For RT-PCR, 5 g of TRIzol-extracted total RNA were used, and cDNA amplification was performed using 35 cycles consisting of 30 s each at 94°C, 56°C, and 72°C followed by a 10-min incubation at 72°C. The amplified DNA fragments were analyzed without further purification by electrophoresis on a 1.5% agarose gel and visualized using a MultiImage Light Cabinet DE-400 (Alpha Innotech Co.). Western blots were probed with a mouse monoclonal antibody to hMMP-2 (Fuji clone 42-5D11 from Medicorp, Montreal, Canada) and an alkaline phosphatase-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA), which were incubated with the nitrocellulose membranes for 60 and 45 min, respectively. For gelatin zymography 50ϫ concentrated SF-conditioned media harvested after cell culture for 48 h were used.
Cell Migration and Invasion Assays-Tumor cells (5 ϫ 10 4 cells in SF-RPMI containing 0.2% bovine serum albumin) were plated onto 8-m Nucleopore filters (Transwell, Corning, Acton, MA) uncoated or precoated with 7.5 g of human placental type IV collagen (Sigma Chemical Co.). The filters were placed in 24-well plates, incubated for 24 h at 37°C with 10 ng/ml IGF-I in the lower chamber, and then fixed with 0.1% glutaraldehyde. After removal of the cells from the upper surface of the filters with a cotton swab, the cells on the lower surface were stained with 0.2% crystal violet and counted with the aid of a Nikon inverted microscope. Triplicate filters were used for each cell type and assay condition, and 20 random fields were counted per filter. To measure invasion, a similar protocol was used, but the filters were precoated with 0.23 mg/ml Matrigel (Collaborative Research, Bedford, MA) and incubation was at 37°C for 48 h.
Experimental Metastasis Assays-Mice were anesthetized by an intramuscular injection of a mixture of 12.5 mg/kg ketamine (Ketalean, MTC Pharmaceuticals, Cambridge, Ontario, Canada) 15 mg/kg xylazine (Rompun, Bayer Inc., Etobicoke, Ontario, Canada), and 2 mg/kg acepromazine maleate (Atravet, Ayerst Laboratories, Montreal, Canada). Tumor cells (10 5 ) were inoculated by the intrasplenic/portal route, and the animals were splenectomized 1 min later, as we previously described (13, 19) . The mice were sacrificed 14 -16 days later, their livers were removed, and the hepatic metastases were enumerated 
RESULTS

Increased IGF-IR Expression in Transfected M-27
Cells-M-27 cells were transfected with the pCI vector expressing full-length human IGF-IR or IGF-IR cDNA in which tyrosine codons in the kinase or C-terminal domains were substituted with phenylalanine codons. To measure the numbers of IGF-I receptors on the transfected cells, we used a ligand binding assay. The results of these analyses are summarized in Table I . All transfected cell lines expressed increased receptor numbers as compared with control M-27 cells. Receptor numbers in these cells were, in fact, in the range normally expressed on the highly metastatic H-59 carcinoma cells.
Characterization of Transfected Cells-M-27 cells typically grow as clusters of rounded cells and spread poorly in the presence of serum. Following transfection with WT IGF-IR, these cells assumed an elongated fibro-epithelioid morphology akin to that typically seen for the more invasive H-59 cells (Fig. 1A) . To quantitate cell spreading, the cells were added to fibronectin-coated wells and incubated at 37°C, in the presence of serum, for up to 5 h. M-27/IGF-IR WT cells but not control cells began spreading within 1 h of the incubation, reaching maximal levels at 3 h. This increase in cell spreading was abolished in cells expressing IGF-IR Y1135F or IGF-IR Y1131F,Y1135F,Y1136F and was markedly reduced in cells expressing IGF-IR Y1250F,Y1251F or IGF-IR Y1131F (Fig. 1B) . Cellular Migration and Invasion-The contribution of the kinase and C-terminal tyrosines to IGF-I-induced migration and invasion were tested using a Boyden chamber chemotaxis assay and a Matrigel invasion system. M-27 cells expressing WT receptors had a 5.3-fold (Ϯ0.8, n ϭ 5) increase in IGF-Istimulated migration relative to non-transfected cells. Y-F substitutions in kinase domain tyrosines 1135 and 1136 abolished this increase in migration whereas substitutions in tyrosines 1250 and 1251 only partially reduced it (41 Ϯ 11%, Fig. 2A ). This effect was specific to IGF-I-induced migration, because neither overexpression of IGF-IR nor the expression of the mutated receptors significantly altered M-27 migration in response to fibronectin (not shown). Cellular invasion as measured using Matrigel-coated filters increased 5.5-fold (Ϯ1.5, n ϭ 4) in cells expressing the WT receptor. This increase was completely abolished in cells expressing IGF-IR Y1131F and reduced to below background levels in cells expressing IGF-IR Y1135F or IGF-IR Y1131F,Y1135F,Y1136F suggesting that, in these cells, the transfected receptor acted as a dominant negative mutant. However, invasion of cells expressing the Y1250F,Y1251F substitution was only partially reduced relative to cells expressing the WT receptor (54 Ϯ 9%, Fig. 2B) .
Effect of Y-F Substitution on MMP-2 Synthesis-M-27
cells overexpressing the WT receptor expressed elevated levels of MMP-2 mRNA as determined by RT-PCR, and this was reflected in increased protein expression and enzymatic activity as determined by Western blotting and gelatin zymography, respectively. This increase in MMP-2 synthesis was abolished in cells expressing IGF-I receptors with Y-F substitutions in either the kinase domain or in residues Y1250F,Y1251F (Fig. 3) .
Anchorage-independent Growth and the Mitogenic Response to IGF-I-
The mitogenic response to IGF-I was completely abrogated in M-27 cells expressing IGF-IR kinase domain mutations Y1135F or Y1131F,Y1135F,Y1136F and reduced in cells expressing Y1311F. In contrast, Y1250F,Y1251F substitutions did not reduce but could actually augment the receptormediated mitogenic response to IGF-1. In contrast to mitogenicity, clonogenicity in semi-solid agar (anchorage-independent growth), which increased 7-fold in cells expressing the WT (Fig. 4) . Cell Survival-IGF-I can rescue M-27 cells overexpressing the WT receptor from apoptosis induced by serum deprivation. We measured apoptosis in cells expressing mutant receptors using annexin V-based immunostaining and flow cytometry. Results in Fig. 5 show that Y-F substitutions in either the kinase or CЈ-terminal domains abolished the ability of the receptor to rescue cells from apoptosis.
Effect of Receptor Mutations on Metastasis-M-27 cells expressing IGF-IR
WT acquire a liver-colonizing potential absent in the parent line. When the cells were transfected with the Y1131F,Y1135F,Y1136F receptor mutant, the increase in the number of experimental liver metastases due to IGF-IR expression was abolished. Y-F substitutions in residues 1250 and 1251 also inhibited metastasis, reducing it by 90% relative to cells transfected with the WT receptor (Fig. 6) . Furthermore, when the Y1131F,Y1135F,Y1136F mutant receptor was overexpressed in the highly metastatic H-59 cells, we found that it could act as a dominant negative mutant, significantly reducing the ability of these cells to form liver metastase (Table I and Fig. 7 ).
DISCUSSION
The objective of this study was to gain insight into the role that the IGF-IR plays in the regulation of the malignant/ metastatic phenotype by exploring the dependence of different cellular functions that affect metastasis on different domains of the receptor. Cells expressing the triple Y1131F,Y1135F,Y1136F mutant receptor lost all of the IGF-IR-dependent functions measured, and their phenotypes were indistinguishable from, or suppressed relative to, the parent line. A Y1135F substitution had a similar effect whereas a Y1131F mutation reduced IGF-IR-mediated functions only partially. This is in agreement with other reports that identified Tyr-1135 and Tyr-1136 as most critical for the kinase activity of the receptor (13) . The Y1250F,Y1251F substitution had the most striking effect on anchorageindependent growth and survival, which were abolished, as was also observed in other models (26, 30) . Morphologically, the Y1250F,Y1251F cells appeared rounded and failed to spread in the presence of serum. IGF-I-induced DNA synthesis was not reduced and even increased somewhat in cells expressing this mutation whereas migration, invasion, and liver colonization were partially reduced.
Our results, therefore identify three types of IGF-IR-regulated, metastasis-controlling functions in our model: 1) functions such as DNA synthesis, which depend only on an intact kinase domain and are not affected by tyrosines 1250 and 1251 mutations; 2) functions such as anchorage-independent growth, cell spreading, MMP-2 synthesis, and survival, which are abolished when either of the domains is mutated and are therefore dependent equally on an intact kinase domain and on tyrosines 1250 and 1251; and 3) functions such as migration, which are abolished by kinase domain mutations but are only partially reduced by the Y1250F,Y1251F mutation, suggesting that they are enhanced through Y1250F,Y1251F signaling. Some of these results are in agreement with other reports that mapped the mitogenic activity of the receptor exclusively to the kinase domain showing an independence of this activity on the CЈ-terminal residues Tyr-1250 and Tyr-1251 (26) , as well as with reports that identified the CЈ-terminal residues Tyr-1250 and Tyr-1251 as critical for anchorage-independent growth and apoptosis (26, 30, 38) . However, unlike findings in other systems, we did not identify any cellular functions that were independent of an intact kinase domain. M-27 cells expressing the Y1135F or Y1131F,Y1135F,Y1136F receptors had a complete abrogation of the mitogenic response, colony formation in agar, cell rescue from apoptosis, cell migration, and invasion. This is at variance with a recent report (30) , which found that a receptor mutated in the kinase domain could still provide cell survival signals in a B cell lymphoma or a fibroblast cell model, as long as the tyrosines in positions 1250 and 1251 remained intact. These differences may reflect unique properties of the different cell types (39) or may be related to differences in the apoptotic triggers used in these studies.
Of interest are our findings that MMP-2 synthesis in M-27 cells expressing the Y1250F,Y1251F receptor mutant were reduced to background levels whereas their invasion in response to IGF-I was only partially reduced as compared with cells expressing the wild type receptor. Receptor and substrate autophosphorylation and the engagement of the MAP kinase and phosphoinositide 3-kinase signaling pathways were reportedly unaltered in fibroblasts expressing an IGF-I receptor mutated 
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on these residues (40) . This suggests that MMP-2 synthesis and other functions affected by Y1250F,Y1251F mutations may depend on multiple signaling pathways that could include the MAP and phosphoinositide 3-kinase pathways, as well as signals recruited by the C-terminal tyrosines. The observed increase in invasion of these cells, despite background (undetectable) levels of MMP-2, may reflect their partially increased IGF-I-dependent migration and suggests that other extracellular matrix-degrading proteinases may be involved. Indeed, we recently observed that M-27 cells produce a weak gelatinolytic activity, which migrates at the molecular mass range of 92,000 kDa and is immunoreactive with an anti-MMP-9 antiserum. This activity could not be detected in M-27 cells expressing the WT IGF-I receptor (or in H-59 cells) but reappeared in cells expressing the mutated receptor. 2 It is conceivable, therefore, that the activity of this enzyme, when combined with the partial increase in migration, is sufficient to render these cells more invasive than parental M-27 cells.
The functions impaired by substitution of Y1250F,Y1251F, namely, spreading, anchorage-independent growth, survival, and migration, suggest that this region of the receptor may be involved in the regulation of cellular functions involving the cytoskeleton and therefore may participate in cross-talk mechanisms between IGF-IR and integrins. This is in agreement with recent observations by Blakesley et al. (40) . Cooperative regulation of cell migration by integrins and the IGF-IR has been demonstrated in various cellular systems. IGF-I has been identified as a regulator of the expression and activation states of several integrins (41) (42) (43) and linked to cellular migration on different substrata, including vitronectin (44 -46) and type IV collagen (42) . In addition, IGF-I was shown to enhance integrin-mediated activation of signal-transducing molecules such as Shc and co-localization of IGF-IR, integrins, and Shc, presumably in focal adhesions (47) . IGF-IR has been implicated in the phosphorylation of the pp125 focal adhesion kinase (48, 49) and may also be linked to integrin-mediated signaling through its substrate Crk II, an SH2/SH3 domain-containing protein, which is phosphorylated in response to IGF-I and associates with the focal adhesion proteins paxillin and p130 Cas (50 -53) . It is conceivable that tyrosine residues 1250 and 1251 are involved in stabilizing the physical interaction between IGF-IR and focal adhesion proteins thereby serving to bridge the two signaling systems. This may also explain the importance of these residues to cell survival, because integrins may amplify IGF-I-triggered survival signals through activation of the phosphoinositide 3-kinase-Akt-Bad pathway (54, 55) .
The impact of these mutations on the metastatic phenotype in vivo is also of interest. We found that M-27 cells overexpressing IGF-IR acquired a high liver-colonizing potential that was abolished in cells expressing the Y1131F,Y1135F,Y1136F mutant receptors. However, cells expressing the Y1250F,Y1251F mutant receptor, although they gave rise to significantly less liver colonies, retained an increased metastatic ability relative to parental M-27 cells (Fig. 6) . Thus, the effect of this mutation on liver colonization did not accurately mimic the effects on anchorage-independent growth and survival, suggesting that retention of increased mitogenic and motogenic responses and an enhanced invasive potential provided these cells with some growth advantage in the liver, relative to parental M-27 cell.
In cells expressing kinase domain-mutated receptors, biological functions such as migration and invasion were not restored to, but rather were suppressed relative to, the parent M-27 cells. Similarly, in cells expressing the Y1250F,Y1251F mutant receptor, anchorage-independent growth was totally abolished. This suggests that the mutated receptors are dominant negative for their respective functions, as was also observed by other investigators (28) . In our studies, this was also noted with the highly metastatic H-59 cells, which normally express high constitutive levels of the receptor. In these cells, expression of the kinase domain mutant receptor suppressed the mitogenic response of the tumor cells in vitro and significantly reduced their metastatic ability in vivo. These results indicate that genetic manipulation of tumor cells in vivo to express high levels of the mutated receptor could potentially provide an effective strategy for inhibition and treatment of metastatic disease.
FIG. 7. An IGF-IR with Y-F substitutions in the kinase domain acts as a dominant negative and inhibits metastases formation.
A, H-59 cells overexpressing the WT or mutated receptors were analyzed by the thymidine uptake assay (A) as described in the legend to Fig. 4 . Shown are the results of a representative experiment of two performed expressed as means and S.D. of triplicates. These cells were also injected by the intrasplenic/portal route to generate liver metastases (B) using the protocol described in the legend to Fig. 6 . Seven mice were injected per group, and all mice developed hepatic metastases.
